Oncostellae

Pipeline

Pipeline

OST-122     (IBD, fibrosis, CRC)

Oral, GI-restricted JAK3/TYK2-ARK5 inhibitor

DISCOVERY 100%
PRECLINICAL 100%
PHASE I 100%
PHASE II 5%

OST-502    (CRPC, Immune Activation)

Oral, non-steroidal GR pure antagonist

DISCOVERY 95%
PRECLINICAL 5%
PHASE I 0%
0%

OST-476    (COPD, severe asthma)

Inhaled, lung-restricted JAK3 inhibitor

DISCOVERY 70%
PRECLINICAL 0%
PHASE I 0%
0%